Combined Therapy with Anti-PD1 and BRAF ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Title :
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
Author(s) :
Huynh, Sandra [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Mortier, Laurent [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Dutriaux, Caroline [Auteur]
CHU Bordeaux
Maubec, Eve [Auteur]
Service de dermatologie [Avicenne]
Boileau, Marie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dereure, Olivier [Auteur]
Pathogénèse et contrôle des infections chroniques (PCCI)
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Leccia, Marie-Therese [Auteur]
Hôpital Michallon
Arnault, Jean-Philippe [Auteur]
Service de dermatologie [CHU d'Amiens-Picardie]
Brunet-Possenti, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Aubin, Francois [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Dreno, Brigitte [Auteur]
Service de dermatologie [Nantes]
Beylot-Barry, Marie [Auteur]
CHU Bordeaux
Lebbe, Celeste [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Lefevre, Wendy [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Delyon, Julie [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Mortier, Laurent [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Dutriaux, Caroline [Auteur]
CHU Bordeaux
Maubec, Eve [Auteur]
Service de dermatologie [Avicenne]
Boileau, Marie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dereure, Olivier [Auteur]
Pathogénèse et contrôle des infections chroniques (PCCI)
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Leccia, Marie-Therese [Auteur]
Hôpital Michallon
Arnault, Jean-Philippe [Auteur]
Service de dermatologie [CHU d'Amiens-Picardie]
Brunet-Possenti, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Aubin, Francois [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Dreno, Brigitte [Auteur]
Service de dermatologie [Nantes]
Beylot-Barry, Marie [Auteur]
CHU Bordeaux
Lebbe, Celeste [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Lefevre, Wendy [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Delyon, Julie [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Journal title :
Cancers
Pages :
1666
Publisher :
MDPI
Publication date :
2020
ISSN :
2072-6694
English keyword(s) :
BRAF inhibitor
MEK inhibitor
anti-PD1
melanoma
targeted therapy
MEK inhibitor
anti-PD1
melanoma
targeted therapy
HAL domain(s) :
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie
Sciences du Vivant [q-bio]/Immunologie/Immunothérapie
Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie
Sciences du Vivant [q-bio]/Immunologie/Immunothérapie
Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
English abstract : [en]
Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. ...
Show more >Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line in real-life clinical practice. We conducted a study within the prospective French multicentric MelBase cohort, including patients treated with a combination of anti-PD1 (pembrolizumab/nivolumab) and BRAF inhibitor (BRAFi: dabrafenib/vemurafenib) and/or MEK inhibitors (MEKi: trametinib/cobimetinib) for BRAF mutated or wild-type advanced melanoma. Fifty-nine patients were included: 30% received the triple combination, 34% an anti-PD1 and BRAFi, and 36% an anti-PD1 and MEKi. Grade 3–4 adverse events occurred in 12% of patients. Permanent discontinuation or dose reduction of one of the treatments for toxicity was reported in 14% and 7% of patients, respectively. In the BRAF wild-type subgroup, treatment with MEKi and anti-PD1 induced a tumor control rate of 83% and median progression-free survival of 7.1 months. The combination of anti-PD1 and BRAFi and/or MEKi was a safe rescue line for advanced melanoma patients previously treated with ICI/TT. The benefit of these combinations, specifically anti-PD1 and MEKi in BRAF wild-type melanoma patients, needs to be prospectively studied.Show less >
Show more >Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line in real-life clinical practice. We conducted a study within the prospective French multicentric MelBase cohort, including patients treated with a combination of anti-PD1 (pembrolizumab/nivolumab) and BRAF inhibitor (BRAFi: dabrafenib/vemurafenib) and/or MEK inhibitors (MEKi: trametinib/cobimetinib) for BRAF mutated or wild-type advanced melanoma. Fifty-nine patients were included: 30% received the triple combination, 34% an anti-PD1 and BRAFi, and 36% an anti-PD1 and MEKi. Grade 3–4 adverse events occurred in 12% of patients. Permanent discontinuation or dose reduction of one of the treatments for toxicity was reported in 14% and 7% of patients, respectively. In the BRAF wild-type subgroup, treatment with MEKi and anti-PD1 induced a tumor control rate of 83% and median progression-free survival of 7.1 months. The combination of anti-PD1 and BRAFi and/or MEKi was a safe rescue line for advanced melanoma patients previously treated with ICI/TT. The benefit of these combinations, specifically anti-PD1 and MEKi in BRAF wild-type melanoma patients, needs to be prospectively studied.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- https://hal.umontpellier.fr/hal-03257701/document
- Open access
- Access the document
- https://hal.umontpellier.fr/hal-03257701/document
- Open access
- Access the document
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352575/pdf
- Open access
- Access the document
- https://hal.umontpellier.fr/hal-03257701/document
- Open access
- Access the document
- document
- Open access
- Access the document
- cancers-12-01666-v2.pdf
- Open access
- Access the document
- Open access
- Access the document